Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
High volume?
I wonder what is their forecast for "interim blinded data"...
Who is optum?
Great price up today! Lol.
Anyone is free to watch how his/her investment did and decide who has been more right in predicting the stock trend.
You bet, strong upward today!
IMO it must mean P3 results great! Lol
Was useless anyway.
Al4oor sometimes I have a hard time in understanding if you are serious or not in your posts.
Don't you think Asco 2020 could be a nice venue?
Right, usually news is released 100 miles within hometown.
Having poor arguments? I know it's tough.
Very plausible, lol.
It's nice to see some humour when a stock plummets from 12 to 0.16.
Lol, you mean they are waiting for more dilution? Come on flip.
Obviously yes, since it is a material event, that's why I have no clue on why flip came up with this other fantasy thought.
ARGS on fire for update at SITC.
I don't know if you are doing this on purpose, if yes please stop it.
Ex is absolutely correct.
The presentation stated minimum of 233 OS events expected and minimum threshold expected to be reached in first half of July/mid-summer (approx 2 OS event per month). The same presentation reported 231 OS events, a few lost to follow-up).
The presentation was in June. Mid-Summer is at worst first half of August, so with 2 events per month it was either 104 or 102 (the latter is what the majority in here believe).
Besides it, having enrolled 331 patients and having 231 OS events with a few lost to follow-up, that number I believe should even be considered lower.
There's no way it was 108, unless you are refuting to understand what was explicitely said.
You can go check yourself in the presentation, slide 13.
Lol 108. IMO complete BS.
Lol, isn't it obvious that it impossible that the parties knew since 2 years about efficacy and let the trial go anyway? I mean, is this message board becoming a complete joke or what?
It was their choice to choose PFS as a primary.
There are already cases in which companies asked and were allowed to switch endpoints before trial end in immunotherapy, Neostem's PII in HF is an example.
I believe PFS as a primary in cancer's immunotherapy trials is nonsense, but we already know that the trial IMO has some flaws in its design.
It all now depends on how the FDA will want to look at the whole thing. Question is: will this trial ever come to an end and produce some tangible positive results?
So you think the video is wrong?
A little bit akward.
I do not believe it was about futility itself and I even might agree with those that believe there has never been a futility rec.
What I believe is that they somehow saw this unexpected activity, which by standard measures was confounded with increase in tumor size. I believe they even thought that for some unknown reasons, they first thought that the drug could even shorten the PFS timeframe and thus be even potentially harmful, for some unknown reasons. However, since they were living longer, they stopped enrollment but let the trial go for those already randomized.
Now it seems that it is almost a fact that many (don't know what %) of these progressors where pseudos, thus there's nothing wrong about the drug itself (and to this extent I believe it might have really be the company's choice to not enroll the remaining patients for timing reasons). I do not know if this will be enough and anyhow if they will be able to redetermine those PFS pseudos for trial purposes.
However one thing is certain, if the trial falls short for PFS and has a very meaningful OS, this consideration should help the FDA to see the whole thing with some more insights that could, perhaps, lead to some form of approval.
This is the positive part. The negative part is that I do believe that cash on hand is almost dried up. I also believe that most trials didn't start for cash reasons. So I believe investors are stuck. Without news in the following days, which I still believe and hope it is the the very possibilities, things would look extremely bleak meaning that I believe many will never recoup. Without news, I see the high probability for a R/S and a huge dilution.
This is obviously all my own opinion.
In the meanwhile trials from other drugs advance and if they don't move to seek approval IMO there would be no chance for grabbing market share.
At this point I would find weird to release PFS before interim blinded data.
The more I read the message board, the more I get the idea that more and more people are somehow growing a negative sentiment...
Because in 2015 that wasn't clear yet.
I knew I would have had a bad news today.
No, progressed placebos who decided to have L already had their PFS measure. And if the drug works then OS would be longer. So no effect on OS because of pseudoprogression.
This is a matter for RK...matters.
So do you agree on my 2 points?
Thank you! Very interesting. In my personal opinion this might explain two most discussed things:
1) IMO the FDA might have imposed an halt because they were seeing progression but was probably convinced not to halt the trial itself because probably they were seeing interesting OS responses;
2) IMO they might have had quite some pseudoprogressors and decided not to unblind PFS because they were reassessing them and perhaps even having talks with the FDA about how to address this problem and solve it before unblinding the whole trial.
By the way, who's talking in the video?
Any conference, the same old posts in this message board. Fact is that who's 'kicking the can' is only these people in this message board. Dreaming is free.
Trying to figure out these kind of things has always been proven wrong in this message board. Why keeping it up? Mistery.
M&A acquirer, lol. Be serious, thos warrants will expire worthless.